Insmed (NASDAQ:INSM) Releases Quarterly Earnings Results, Beats Estimates By $0.61 EPS

Insmed (NASDAQ:INSM) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61, FiscalAI reports. The company had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative return on equity of 122.43% and a negative net margin of 76.94%.Insmed’s revenue was up 296.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.70) EPS.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI launch momentum accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, with approximately 7,000 new patient starts and more than 6,300 cumulative prescribers. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.4 billion from above $1 billion.
• Insmed increased its estimated global peak sales opportunity for BRINSUPRI to more than $7 billion, citing expanding diagnosis, strong persistence and payer access, and the potential for broader use among patients with comorbid COPD or asthma. The company said prescribing depth and refill behavior are tracking at or ahead of internal expectations.
• TPIP data strengthened the company’s confidence in its pipeline centerpiece. In a 12-month PAH open-label extension, patients maintained or improved efficacy measures, 65% reached refined low-risk status, treatment continuation was 91%, and no new safety signals emerged; Phase III programs in PAH and PH-ILD are enrolling, with PPF and IPF studies planned.
• ARIKAYCE revenue rose 8% year over year to $116.3 million, while Insmed reiterated 2026 guidance of $450 million–$470 million. The company has submitted for a U.S. label expansion into newly diagnosed MAC lung disease and expects a Japanese submission in the second half of 2026, potentially supporting launches in 2027.
• Insmed reported approximately $1.2 billion in cash and reiterated expectations for cash-flow positivity in 2027 without additional capital raises, despite planned investment in TPIP Phase III trials, BRINSUPRI advertising, and Japanese commercial infrastructure. Management also noted that European commercialization is less attractive because of budget constraints and limited willingness to pay for innovation.

Insmed Trading Down 1.1%

INSM traded down $1.45 during trading on Friday, reaching $131.10. 4,904,073 shares of the company’s stock were exchanged, compared to its average volume of 3,072,772. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed has a one year low of $90.39 and a one year high of $212.75. The firm has a fifty day moving average price of $105.14 and a two-hundred day moving average price of $129.23. The stock has a market capitalization of $28.42 billion, a PE ratio of -31.90 and a beta of 0.81.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $218.00 price target on shares of Insmed in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $235.00 target price on shares of Insmed in a research note on Tuesday, July 28th. Wells Fargo & Company boosted their target price on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $175.00 price target on shares of Insmed in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Insmed has an average rating of “Buy” and a consensus target price of $205.26.

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer directly owned 98,603 shares in the company, valued at $10,084,128.81. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the transaction, the insider directly owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 54,590 shares of company stock worth $5,793,738. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC grew its position in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the period. Transamerica Financial Advisors LLC raised its holdings in shares of Insmed by 72.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 146 shares during the period. Brooklyn Investment Group raised its holdings in shares of Insmed by 5.7% in the 4th quarter. Brooklyn Investment Group now owns 2,839 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 152 shares during the period. Raiffeisen Bank International AG purchased a new position in Insmed in the fourth quarter valued at approximately $32,000. Finally, Insigneo Advisory Services LLC lifted its stake in Insmed by 10.2% in the fourth quarter. Insigneo Advisory Services LLC now owns 2,641 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 245 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.